Patents by Inventor David William Will

David William Will has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7241882
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: July 10, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20070072866
    Abstract: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase —3? (GSK-3?) which is believed to cause the neurodegeneration that results in these diseases.
    Type: Application
    Filed: August 28, 2006
    Publication date: March 29, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Karl SCHOENAFINGER, Swen HOELDER, David William WILL, Hans MATTER, Guenther MUELLER, Martin BOSSART
  • Patent number: 7067665
    Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W-U-V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: June 27, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Nazare, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Patent number: 6953857
    Abstract: The present invention relates to compounds comprising the following formula: R0—Q—X—Q?—W—U—V—G—M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: October 11, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazaré, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Patent number: 6906084
    Abstract: The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: June 14, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazaré, Melanie Essrich, David William Will, Hans Matter, Kurt Ritter, Volkmar Wehner
  • Patent number: 6905820
    Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: June 14, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20040265885
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Application
    Filed: June 9, 2004
    Publication date: December 30, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20040176377
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) 1
    Type: Application
    Filed: November 19, 2003
    Publication date: September 9, 2004
    Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David William Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi
  • Patent number: 6777544
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: August 17, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Patent number: 6747148
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 8, 2004
    Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6723706
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 20, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Anuschirwan Peyman, David William Will, Esther Chang, Kathleen Pirollo, Antonina Rait
  • Patent number: 6660728
    Abstract: The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R1, R2, R4, R6, A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: December 9, 2003
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20030199689
    Abstract: The present invention relates to compounds of formula I, 1
    Type: Application
    Filed: November 21, 2002
    Publication date: October 23, 2003
    Inventors: Marc Nazare, Melanie Essrich, David William Will, Hans Matter, Kurt Ritter, Volkmar Wehner
  • Publication number: 20030153557
    Abstract: The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R1, R2, R4, R6, A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 14, 2003
    Applicant: Aventis Pharma Deutschland GmbH and Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6566366
    Abstract: Compounds of the formula and salts thereof wherein the substituents are defined as in accordance with the specification useful for the treatment of tumor growth, osteoporosis, inflammation and cardiovascular disorders.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: May 20, 2003
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20030064514
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Hs-ras gene and mRNA, and its use to specifically regulate, modulate, or inhibit expression of the Ha-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Application
    Filed: February 17, 2000
    Publication date: April 3, 2003
    Applicant: HOECHST MARION ROUSSEL DEUTSCHLAND GmbH
    Inventors: EUGEN UHLMANN, ANUSCHIRWAN PEYMAN, DAVID WILLIAM WILL, ESTHER CHANG, KATHLEEN PIROLLO, ANTONINA RAIT
  • Publication number: 20030022172
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Application
    Filed: April 17, 2001
    Publication date: January 30, 2003
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20020198195
    Abstract: The present invention relates to compounds comprising the following formula:
    Type: Application
    Filed: December 21, 2001
    Publication date: December 26, 2002
    Inventors: Marc Nazare, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Publication number: 20020187473
    Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
    Type: Application
    Filed: April 17, 2001
    Publication date: December 12, 2002
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20020173656
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: December 6, 2001
    Publication date: November 21, 2002
    Inventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi